{"analyses":[{"ciLowerLimit":"0.729","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.349","groupDescription":"Tablet (test) versus Capsule (reference)","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.9623","paramType":"pairwise GMR","paramValue":"0.992","statisticalComment":"1-factor ANOVA of log-transformed, dose-normalized data (factor = formulation)","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.23","value":"2170"}]}],"title":"Capsule"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.29","value":"2150"}]}],"title":"Tablet"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Cmax was defined as the maximum observed concentration of INCB001158.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors. Participants enrolled in Part 2D received INCB001158 tablets from C1D1 to C1D15, and then switched to INCB001158 capsules starting on C1D16 onwards.","id":"OG000","title":"Part 2D: INCB001158 100 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Population","reportingStatus":"POSTED","timeFrame":"Tablet: Cycle 1 Day 15 (Tablet) and Cycle 2 Day 1 (Capsule): predose; 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose","title":"Cmax of INCB001158 for Capsules Versus Tablets for Part 2D to Assess the Effect of Formulation","type":"SECONDARY","unitOfMeasure":"ng/mL"}